Tianjin Holder Pharmaceutical Technology Co. Ltd.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of acipimox capsule test formulation (specification: 0.25g, applicant: Tianjin Palm Pharmaceutical Technology Co., Ltd.) and reference formulation (trade name: Olbetam®, specification: 0.25g, licensee: Pfizer Limited) after single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of acipimox capsule test formulation (specification: 0.25g) and reference formulation (trade name: Olbetam®, specification: 0.25g) in healthy Chinese adult subjects.

(1) Primary objective: To evaluate the pharmacokinetic characteristics of the test and reference preparations after a single oral administration in healthy subjects in the fasting and postprandial state, using sacubitril-valsartan sodium tablets provided by Tianjin Palm Pharmaceutical Technology Co., Ltd. as the test preparation (T) and sacubitril-valsartan sodium tablets (trade name: Nusintuo) licensed by Novartis Pharma Schweiz AG and produced by Novartis Farma S.p.A. as the reference preparation (R). (2) Secondary objective: To investigate the safety of the test and reference preparations after oral administration in healthy subjects.